Anaemia following Artemisinin-Based Combination Treatments of Uncomplicated < b > < i > Plasmodium falciparum < /i > < /b > Malaria in Children: Temporal Patterns of Haematocrit and the Use of Uncomplicated Hyperparasitaemia as a Model for Evaluating Late-Appearing Anaemia
Background: In severe malaria, intravenous artesunate may cause delayed haemolytic anaemia but there has been little evaluation of the propensity of oral artemisinin-based combination treatments (ACTs) to cause late-appearing anaemia.Methods: The frequency of anaemia (haematocrit (Source: Chemotherapy)
Source: Chemotherapy - April 27, 2017 Category: Cancer & Oncology Source Type: research
Dynamics of < smlcap > L < /smlcap > -Carnitine in Plasma and Urine in Patients Undergoing Cisplatin Chemotherapy
Conclusions: CDDP transiently increased plasma LC levels. The mechanism seemed to involve recruitment for marked urinary loss of LC. However, these changes in plasma and urinary LC levels were not related to clinical factors, suggesting that the dynamics of LC were independent of preexisting physical parameters.Chemotherapy 2017;62:225-230 (Source: Chemotherapy)
Source: Chemotherapy - April 18, 2017 Category: Cancer & Oncology Source Type: research
Retrospective Analysis of the Risk Factors for Grade IV Neutropenia in Oesophageal Cancer Patients Treated with a Docetaxel, Cisplatin, and 5-Fluorouracil Regimen
Background: Previous Japanese trials of the docetaxel, cisplatin, and 5-fluorouracil regimen for oesophageal cancer have demonstrated that a large proportion of patients also develop grade IV neutropenia. Our aim was to examine the risk factors for neutropenia in patients treated with this regimen.Methods: We retrospectively analysed the risk factors for developing grade IV neutropenia in 66 patients with oesophageal cancer using a multivariate analysis.Results: After administering the docetaxel, cisplatin, and 5-fluorouracil regimen, 49 patients (74.2%) developed grade IV neutropenia. Grade IV neutropenia was significantl...
Source: Chemotherapy - April 18, 2017 Category: Cancer & Oncology Source Type: research
Expanding the Role of Chloroquine as a Potent Antineoplastic Agent in Different Gastrointestinal Malignancies
Chemotherapy 2017;62:214 (Source: Chemotherapy)
Source: Chemotherapy - April 11, 2017 Category: Cancer & Oncology Source Type: research
Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy
Background: In patients with non-small-cell lung cancer (NSCLC), the effects of second-line chemotherapy on overall survival (OS) might be confounded by subsequent therapies. Therefore, using individual-level data, we aimed to determine the relationships between progression-free survival (PFS) and post-progression survival (PPS) with OS in patients with advanced NSCLC treated with docetaxel monotherapy as second-line chemotherapy.Methods: Between April 2002 and December 2014, data from 86 patients with advanced NSCLC who underwent second-line docetaxel monotherapy following first-line treatment with platinum combination ch...
Source: Chemotherapy - April 5, 2017 Category: Cancer & Oncology Source Type: research
Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients
Conclusion: Taxane-based chemotherapy regimens seem to increase macular thickness, with a relative sparing of the fovea, in patients without significant macular edema. Further research is required to better explain the pathophysiology and possible impact of this phenomenon.Chemotherapy 2017;62:199-204 (Source: Chemotherapy)
Source: Chemotherapy - March 28, 2017 Category: Cancer & Oncology Source Type: research
Hypoxia Induces Multidrug Resistance via Enhancement of Epidermal Growth Factor-Like Domain 7 Expression in Non-Small Lung Cancer Cells
Chemotherapy is widely used in non-small cell lung cancer (NSCLC) treatment, yet multidrug resistance (MDR) is a major chemotherapeutic obstacle in both resectable and advanced NSCLC. Epidermal growth factor-like domain 7 (EGFL7), also known as vascular endothelial stain, is an endothelial cell-derived secreted factor that regulates vascular tube formulation. The aim of this study was to investigate the potential relationships between EGFL7 and MDR in NSCLC cells. We first obtained the CDDP-based MDR phenotype cell line A549/CDDP by repeated exposure to a proper concentration of CDDP (cisplatin) from original A549 cells. T...
Source: Chemotherapy - March 28, 2017 Category: Cancer & Oncology Source Type: research
Do You Know Pixantrone
Chemotherapy 2017;62:192-193 (Source: Chemotherapy)
Source: Chemotherapy - March 24, 2017 Category: Cancer & Oncology Source Type: research
In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives
Conclusion: Compounds obtained by modifications on C-7 of norfloxacin with the acetylated piperazinyl, halogen atoms, and substituted hydrazinyl showed good in vitro activity - some even better than the original compound.Chemotherapy 2017;62:194-198 (Source: Chemotherapy)
Source: Chemotherapy - March 23, 2017 Category: Cancer & Oncology Source Type: research
Do You Know Pixantrone?
Chemotherapy 2017;62:192-193 (Source: Chemotherapy)
Source: Chemotherapy - March 23, 2017 Category: Cancer & Oncology Source Type: research
Single-Agent Pixantrone as a Bridge to Autologous Stem Cell Transplantation in a Patient with Refractory Diffuse Large B-Cell Lymphoma
We report a case of aggressive non-Hodgkin lymphoma refractory to first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and second-line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) chemotherapy treatments. The patient achieved remission with single-agent pixantrone, and received a consolidation with high-dose BEAM (BCNU, etoposide, cytarabine, and melphalan) chemotherapy and autologous stem cell transplantation. He received consolidation radiotherapy on the site of bulky disease. At 20 months from transplant, the disease is in continuous complete remission. The successful...
Source: Chemotherapy - March 23, 2017 Category: Cancer & Oncology Source Type: research
Expression of Activating Protein 4 and Its Relationships with Prognosis in Gastric Cancer
Objective: The aim of this work was to investigate the expression of transcription activating protein 4 (AP-4) in gastric cancer (GC) and its impacts on prognosis.Methods: The cancer tissues and normal tissues of 54 GC patients were sampled for the expression detection of AP-4, and the patients were followed up.Results: The positive expression rate of AP-4 in the cancer tissues (68.5%) was higher than the normal tissues (22.2%;p (Source: Chemotherapy)
Source: Chemotherapy - March 23, 2017 Category: Cancer & Oncology Source Type: research
Coronary Spasm after an Injection of Vincristine
We report an episode of coronary spasm due to vincristine, a vinca alkaloid, in a 49-year-old man treated for a diffuse undifferentiated carcinoma. The patient suffered recurrent episodes of typical chest pain with ST-elevation in the inferior area. Coronary spasm was confirmed by an angiogram, which showed normal coronary arteries. No recurrence occurred with the medical management. Coronary spasm induced by vincristine is a newly described facet of chemotherapy-related cardiotoxicity.Chemotherapy 2017;62:169-171 (Source: Chemotherapy)
Source: Chemotherapy - January 31, 2017 Category: Cancer & Oncology Source Type: research
Primary Prevention Strategies for Anthracycline Cardiotoxicity: A Brief Overview
The clinical use of doxorubicin and other antitumor anthracyclines is limited by a dose-related risk of cardiomyopathy and heart failure which may occur “on treatment” or any time, from months to years, after completing chemotherapy. Dose reductions diminish the incidence of cardiac events attributable to anthracyclines, but heart failure still occurs in some patients exposed to low or moderate anthracycline doses. Because anthracyclines improve the life expectancy of patients with, for example, breast cancer or lymphomas, preventing or diminishing the risk of early or delayed cardiotoxicity is of obvious clinical impo...
Source: Chemotherapy - January 25, 2017 Category: Cancer & Oncology Source Type: research
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution
Conclusion: Del19 and L858R have distinct prognostic implications and may require individual therapeutic strategies.Chemotherapy 2017;62:151-158 (Source: Chemotherapy)
Source: Chemotherapy - January 23, 2017 Category: Cancer & Oncology Source Type: research
